Ticker | Status | Jurisdiction | Filing Date | CP Start | CP End | CP Loss | Deadline |
---|
Ticker | Case Name | Status | CP Start | CP End | Deadline | Settlement Amt |
---|
Ticker | Name | Date | Analyst Firm | Up/Down | Target ($) | Rating Change | Rating Current |
---|
Investors with a lot of money to spend have taken a bearish stance on Eli Lilly and Co (NYSE:LLY).
And retail traders should know.
We noticed this today when the trades showed up on publicly available options history that we track here at Benzinga.
Whether these are institutions or just wealthy individuals, we don't know. But when something this big happens with LLY, it often means somebody knows something is about to happen.
So how do we know what these investors just did?
Today, Benzinga's options scanner spotted 19 uncommon options trades for Eli Lilly and Co.
This isn't normal.
The overall sentiment of these big-money traders is split between 21% bullish and 31%, bearish.
Out of all of the special options we uncovered, 3 are puts, for a total amount of $248,755, and 16 are calls, for a total amount of $1,477,703.
Based on the trading activity, it appears that the significant investors are aiming for a price territory stretching from $340.0 to $1040.0 for Eli Lilly and Co over the recent three months.
Assessing the volume and open interest is a strategic step in options trading. These metrics shed light on the liquidity and investor interest in Eli Lilly and Co's options at specified strike prices. The forthcoming data visualizes the fluctuation in volume and open interest for both calls and puts, linked to Eli Lilly and Co's substantial trades, within a strike price spectrum from $340.0 to $1040.0 over the preceding 30 days.
Symbol | PUT/CALL | Trade Type | Sentiment | Exp. Date | Ask | Bid | Price | Strike Price | Total Trade Price | Open Interest | Volume |
---|---|---|---|---|---|---|---|---|---|---|---|
LLY | CALL | TRADE | BEARISH | 06/20/25 | $396.0 | $392.0 | $392.0 | $600.00 | $235.2K | 18 | 0 |
LLY | CALL | TRADE | NEUTRAL | 08/16/24 | $39.3 | $36.9 | $38.07 | $960.00 | $190.3K | 638 | 0 |
LLY | CALL | TRADE | NEUTRAL | 07/19/24 | $18.8 | $14.75 | $16.98 | $950.00 | $169.8K | 1.0K | 51 |
LLY | CALL | SWEEP | NEUTRAL | 08/16/24 | $244.85 | $238.0 | $241.37 | $720.00 | $120.6K | 303 | 7 |
LLY | CALL | SWEEP | NEUTRAL | 08/16/24 | $234.9 | $228.0 | $231.52 | $730.00 | $115.7K | 221 | 7 |
Eli Lilly is a drug firm with a focus on neuroscience, cardiometabolic, cancer, and immunology. Lilly's key products include Verzenio for cancer; Mounjaro, Zepbound, Jardiance, Trulicity, Humalog, and Humulin for diabetes; and Taltz and Olumiant for immunology.
A total of 5 professional analysts have given their take on this stock in the last 30 days, setting an average price target of $908.0.
Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating themselves, adapting their strategies, monitoring multiple indicators, and keeping a close eye on market movements. Stay informed about the latest Eli Lilly and Co options trades with real-time alerts from Benzinga Pro.
Posted In: LLY